Patent classifications
C12N2500/46
METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPY
Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.
STEM CELL DERIVED ISLET DIFFERENTIATION
Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
COMPOSITIONS AND METHODS FOR STABILIZING SUSCEPTIBLE COMPOUNDS
Methods for increasing the stability of, or protecting, labile components, such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium, are described. Stability of the labile compound is increased either, by derivatization or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule or by the use of sequestering agents. Encapsulation can provide controlled release of the susceptible compound being protected. These methods may improve or extend the storage conditions, the shipping and handling of media compositions comprising the labile compounds at room temperature rather than at lower temperatures, thereby decreasing shipping costs.
Bifidobacterium Longum with the Ability to Relieve Atopic Dermatitis and its Application
The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.
Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Reagent kit for step-by-step hUC-MSC culture and hUC-MSC acquired using said reagent kit
A serum-free culture method for human umbilical cord mesenchymal stem cells (hUC-MSC), said method using a step-by-step method to culture hUC-MSC: first using a TME culture medium for culturing for 3-4 hours to promote hUC-MSC adherence, and then switching to a TMD culture medium for rapid amplification.
STEM CELL DERIVED ISLET DIFFERENTIATION
Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
STREAMLINED METHODS FOR MAKING LIQUID MEDIA
Provided herein are, inter alia, methods for preparing a liquid cell culture media that has lesser lot-to-lot analytical variation, increased performance, and has lesser metal ion concentrations compared to a liquid media prepared by traditional methods. Such liquid media may be used for culturing cells, including but not limited to, recombinant cells.